Universität zu Köln

Latteyer, Soeren, Tiedje, Vera, Koenig, Katharina, Ting, Saskia ORCID: 0000-0003-1415-7714, Heukamp, Lukas C., Meder, Lydia, Schmid, Kurt Werner, Fuehrer, Dagmar and Moeller, Lars Christian (2016). Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine, 54 (3). S. 733 - 742. NEW YORK: SPRINGER. ISSN 1559-0100

Full text not available from this repository.

Abstract

Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer with a median survival of 4-6 months. Identification of mutations contributing to aberrant activation of signaling cascades in ATC may provide novel opportunities for targeted therapy. Thirty-nine ATC samples were studied by next-generation sequencing (NGS) with an established gene panel. High quality readout was obtained in 30/39 ATC. Twenty-eight ATC harbored a mutation in at least one of the studied genes: TP53 (18/30), NF1 (11/30), ALK (6/30), NRAS (4/30), ATRX (3/30), BRAF (2/30), HRAS (2/30), KRAS (1/30). In 17/30 ATC (54 %) mutations were found in two or more genes. Twenty-one of the identified variants are listed in COSMIC as somatic mutations reported in other cancer entities. In three ATC samples no mutations were detected and none of the ATCs was positive for BRAF(V600E). The most frequent mutations were found in TP53 (60 %), followed by NF1 (37 %). ALK mutations were detected in 20 % of ATC and were more frequent than RAS or BRAF mutations. ATRX mutations were identified in 10 % of the ATC samples. These sequencing data from 30 ATC samples demonstrate the accumulation of genetic alterations in ATC because in 90 % of samples mutations were already found in the investigated nine genes alone. Mutations were found with high prevalence in established tumor suppressor and oncogenes in ATC, such as TP53 and H/K/NRAS, but also, although less frequent, in genes that may harbor the potential for targeted treatment in a subset of ATC patients, such as ALK and NF1.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Latteyer, Soeren UNSPECIFIED UNSPECIFIED UNSPECIFIED Tiedje, Vera UNSPECIFIED UNSPECIFIED UNSPECIFIED Koenig, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Ting, Saskia UNSPECIFIED orcid.org/0000-0003-1415-7714 UNSPECIFIED Heukamp, Lukas C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Meder, Lydia UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmid, Kurt Werner UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuehrer, Dagmar UNSPECIFIED UNSPECIFIED UNSPECIFIED Moeller, Lars Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-254502
DOI:	10.1007/s12020-016-1080-9
Journal or Publication Title:	Endocrine
Volume:	54
Number:	3
Page Range:	S. 733 - 742
Date:	2016
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1559-0100
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTEGRATIVE GENOMICS VIEWER; LYMPHOMA KINASE; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; GENETIC ALTERATIONS; PAPILLARY CARCINOMAS; V600E MUTATION; LUNG-CANCER; ASSOCIATION; P53; PATHWAY Multiple languages Endocrinology & Metabolism Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/25450